- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.11. | Mustang Bio's MB-108 receives FDA orphan drug status for glioma treatment | ||
| 08.11. | Sonnet BioTherapeutics secures US patent covering two drug candidates | ||
| 08.11. | Santen, Arctic Vision sign deal for ARVN001 to treat UME | ||
| 08.11. | Private equity deals in pharmaceutical in Canada remained flat in Q3 2024 | ||
| 08.11. | Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry | ||
| 08.11. | Q3 2024 update: ecommerce related M&A activity in the pharmaceutical industry | ||
| 08.11. | Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry | ||
| 07.11. | DBV Technologies' stock slides as financial woes worsens | ||
| 07.11. | Vidac secures funding to advance skin cancer trials of novel ointment | ||
| 07.11. | The people-first approach transforming eClinical processes | ||
| 07.11. | GHO and Ampersand Capital to acquire Avid Bioservices | ||
| 07.11. | EMA approves Sanofi/Regeneron's Dupixent for young EoE patients | ||
| 07.11. | DeepMind Nobel Prize winner says AI will have "electricity" type of impact | ||
| 06.11. | Zentiva voices UWWTD concerns as EU grants approval | ||
| 06.11. | Intra-Cellular bolsters Caplyta data with another Phase III win | ||
| 06.11. | Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of drug approvals | ||
| 06.11. | Strong Wegovy revenue growth for Novo Nordisk but shares dip | ||
| 06.11. | GSK CEO addresses declining trust in vaccines following Trump re-election | ||
| 06.11. | Tevogen Bio partners Microsoft for HPV treatment | ||
| 06.11. | Trump triumphs but impact on healthcare industry remains unclear | ||
| 06.11. | Nxera Pharma and Antiverse to design antibodies targeting GPCRs | ||
| 06.11. | GSK's RSV vaccine approved in Canada for adults aged 50 to 59 | ||
| 05.11. | Vertex shares up after full-year product revenue guidance boost | ||
| 05.11. | NLS Pharmaceutics and Kadimastem stocks soar following merger agreement | ||
| 05.11. | Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
